Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Boehringer Ingelheim
Healthtrust
Fish and Richardson
Covington
Cipla
Merck
Queensland Health
Fuji

Generated: November 14, 2018

DrugPatentWatch Database Preview

Salmeterol xinafoate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for salmeterol xinafoate and what is the scope of salmeterol xinafoate patent protection?

Salmeterol xinafoate is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are nineteen drug master file entries for salmeterol xinafoate. Two suppliers are listed for this compound.

Pharmacology for salmeterol xinafoate
Medical Subject Heading (MeSH) Categories for salmeterol xinafoate
Synonyms for salmeterol xinafoate
( inverted exclamation markA) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol xinafoate
(+-)-4-Hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol 1-hydroxy-2-naphthoate (salt)
(+/-) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol xinafoate
1-HYDROXY-2-NAPHTHOIC ACID; SALMETEROL
1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-, 1-hydroxy-2-naphthalenecarboxylate (salt)
2-(Hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol 1-hydroxy-2-naphthoate
2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol; 1-hydroxynaphthalene-2-carboxylic acid
2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol;1-hydroxynaphthalene-2-carboxylic acid
4-(1-Hydroxy-2-((6-(4-phenylbutoxy)hexyl)amino)ethyl)-2-(hydroxymethyl)phenol 1-hydroxy-2-naphthoate
4-[1-Hydroxy-2-[[6-(4-phenylbutoxy)hexyl]amino]ethyl]-2-(hydroxymethyl)phenol 1-Hydroxy-2-naphthoate
4-Hydroxy-?1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol 1-hydroxy-2-naphthalenecarboxylic acid salt
4-Hydroxy-|A1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol 1-Hydroxy-2-naphthalenecarboxylic Acid
4-Hydroxy-alpha-({[6-(4-phenylbutoxy)hexyl]amino}methyl)-1,3-benzenedimethanol xinafoate
4CA-1124
89365-50-4 (Parent)
94749-08-3
AB0020656
AC1L1LPS
AK106977
AKOS016004957
AN-8181
ANW-61823
Arial
Asmerole
BC208521
BCP0726000003
Beglan
Betamican
Bio-0096
C25H37NO4.C11H8O3
C36H45NO7
CAS-94749-08-3
CHEBI:9012
CHEMBL1082607
CS-1527
CTK8B9015
D00687
Dilamax
DSSTox_CID_25798
DSSTox_GSID_45798
DSSTox_RID_81137
DTXSID1045798
EU-0101100
FT-0642283
GR 33343 G
GR 33343G
GR 33343X xinafoate
GR 3343G
GR-33343 G
GR-33343-G
gr-33343g
HMS2232I16
HMS3263K22
HY-17453
Inaspir
KB-280789
LP000477
LP01100
LS-94516
MFCD00897708
MLS001332577
MLS001332578
MolPort-003-850-218
NCGC00015938-05
NCGC00094372-01
NCGC00094372-02
NCGC00094372-03
NCGC00094372-04
NCGC00261785-01
Q-201697
s4296
Salmetedur
Salmeterol (xinafoate)
Salmeterol 1-hydroxy-2-naphthoate
Salmeterol Hydroxynaphthoate
Salmeterol xinafoate (JAN/USAN)
Salmeterol xinafoate [USAN:USP]
Salmeterol xinafoate [USAN]
Salmeterol xinafoate for system suitability, European Pharmacopoeia (EP) Reference Standard
Salmeterol xinafoate, >=98% (HPLC), solid
Salmeterol xinafoate, European Pharmacopoeia (EP) Reference Standard
Salmeterol Xinafoate, Pharmaceutical Secondary Standards; Certified Reference Material
Salmeterol xinafoate, United States Pharmacopeia (USP) Reference Standard
Salmeterol xinafonate
salmeterol, 1-hydroxy-2-naphthoate
Salmeterolxinafoate
SCHEMBL18070
Serevent diskus
Serevent Inhaler and Disks
Siduomi
SMR000875207
SN 408
ST24031610
TC-150568
Tox21_111270
Tox21_111270_1
Tox21_501100
Ultrabeta
V1621
W-5199

US Patents and Regulatory Information for salmeterol xinafoate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Glaxosmithkline SEREVENT salmeterol xinafoate AEROSOL, METERED;INHALATION 020236-001 Feb 4, 1994 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for salmeterol xinafoate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997 ➤ Sign Up ➤ Sign Up
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997 ➤ Sign Up ➤ Sign Up
Glaxosmithkline SEREVENT salmeterol xinafoate AEROSOL, METERED;INHALATION 020236-001 Feb 4, 1994 ➤ Sign Up ➤ Sign Up
Glaxosmithkline SEREVENT salmeterol xinafoate AEROSOL, METERED;INHALATION 020236-001 Feb 4, 1994 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Boehringer Ingelheim
Healthtrust
Fish and Richardson
Covington
Cipla
Merck
Queensland Health
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.